A Phase III trial of Rituxan used in combination with other drugs for lupus nephritis failed to reduce symptoms after a year of treatment, co-developers Genentech and Biogen Idec said. A Biogen spokeswoman said the company is disappointed but not surprised by the results, adding that it will start looking for another potential medicine for lupus.

Related Summaries